Esophageal adenocarcinoma and Barrett's esophagus

Minerva Gastroenterologica e Dietologica

Volumn 53, Issue 2, 2007, Pages 157-169

  Sayana, H ^a   Wani, S ^a   Sharma, P ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Barrett's esophagus; Endoscopy; Esophageal neoplasms; Gastroesophageal reflux disease

Indexed keywords

AMINOPHYLLINE; ANTINEOPLASTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; GLYCERYL TRINITRATE; OMEPRAZOLE; PHOTOFRIN;

ADJUVANT THERAPY; AUTOFLUORESCENCE; BARRETT ESOPHAGUS; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CHROMOENDOSCOPY; CLINICAL TRIAL; CONFOCAL LASER MICROSCOPY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DIETARY INTAKE; DISEASE COURSE; DYSPLASIA; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FEVER; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HIGH RISK POPULATION; HUMAN; LIFESTYLE; OBESITY; ODYNOPHAGIA; PALLIATIVE THERAPY; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PLEURA EFFUSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SURVIVAL RATE; THORAX PAIN;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOSCOPY; HUMANS; INCIDENCE; MASS SCREENING; NEOPLASM STAGING; POPULATION SURVEILLANCE; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 34547758431     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26(5 Suppl 15):2-8.
2. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002;11:235-56.
3. Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol 2003;98:1627-33.
4. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
6. Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004;127:310-30.
7. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985;313:857-9.
8. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-22.
9. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-31.
10. Shaheen NJ. Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 2005;128:1554-66.
11. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
12. El-Serag HB, Mason AC, Petersen N, Key CR. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002;50:368-72.
13. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
14. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF Jr. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274:474-7.
15. Farrow DC, Vaughan TL, Sweeney C, Gammon MD, Chow WH, Risch HA et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000;11:231-8.
16. Clark GW, Smyrk TC, Burdiles P, Hoeft SF, Peters JH, Kiyabu M et al. Is Barrett's metaplasia the source of adenocarcinomas of the cardia? Arch Surg 1994;129:609-14.
17. Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS et al. Extent of high-grade dysplasia in Barren's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
18. Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992;33:1155-8.
19. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883-90.
20. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:872-8.
21. Chak A, LeeT, Kinnard MF, Brock W, Faulx A, Willis J et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002;51:323-8.
22. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002;123:461-7.
23. El-Serag HB, Kvapil P, Hacken-Bitar J, Kramer JR. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005;100:2151-6.
24. Stein DJ, El-Serag HB, Kuczynski J, Kramer JR, Sampliner RE. The association of body mass index with Barrett's oesophagus. Aliment Pharmacol Ther 2005;22:1005-10.
25. Smith KJ, O'Brien SM, Smithers BM, Gotley DC, Webb PM, Green AC et al. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2005;14(11 Pt 1):2481-6.
26. Terry P, Lagergren J, Hansen H, Wolk A, Nyren O. Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers. Eur J Cancer Prev 2001;10:365-9.
27. Whanger PD. Selenium and its relationship to cancer: an update dagger. Br J Nutr 2004;91:11-28.
28. Chow WH, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998;58:588-90.
29. Weston AP, Badr AS, Topalovski M, Cherian R, Dixon A, Hassanein RS. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 2000;95:387-94.
30. Richter JE, Falk GW, Vaezi MF. Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am J Gastroenterol 1998;93:1800-2.
31. Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004;96:388-96.
32. Vicari JJ, Peek RM, Falk GW, Goldblum JR, Easley KA, Schnell J et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998;115:50-7.
33. Wu AH, Crabtree JE, Bernstein L, Hawtin P, Cockburn M, Tseng CC et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer 2003;103:815-21.
34. Lagergren J, Bergstrom R, Adami HO, Nyren O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000;133:165-75.
35. Corley DA, Levin TR, Habel LA, Buffler PA et al. Barrett's esophagus and medications that relax the lower esophageal sphincter. Am J Gastroenterol 2006;101:937-44.
36. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995;4:85-92.
37. Brown LM, Silverman DT, Pottern LM, Schoenberg JB, Greenberg S, Swanson GM et al. Adenocarcinoma of the esophagus and esophagogastric junction in white men in the United States: alcohol, tobacco, and socioeconomic factors. Cancer Causes Control 1994;5:333-40.
38. Rabat GC, Ng SK, Wynder EL. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control 1993;4:123-32.
39. Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 2001;12:721-32.
40. Lagergren J, Bergstrom R, Lindgren A, Nyren O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000;85:340-6.
41. Freedman ND, Abnet CC, Leitzmann MF, Mouw T, Subar AF, Hollenbeck AR et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2007 Apr 9; [Epub ahead of print].
42. Romero Y, Cameron AJ, Locke GR 3rd, Schaid DJ, Slezak JM, Branch CD et al. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 1997;113:1449-56.
43. Chak A, Ochs-Balcom H, Flak G, Grandy WM, Kinnard M, Willis JE et al. Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev 2006;15:1668-73.
44. Soni A, Sampliner RE, Sonnerberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective? Am J Gastroenterol 2000;95:2086-93.
45. Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol 1997;92:27-31.
46. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barren's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997;92:1293-7.
47. Chak A, Faulx A, Eng C, Grady W, Kinnard M, Ochs-Balcom H et al. Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. Cancer 2006;107:2160-6.
48. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992;103:1241-5.
49. Guardino JM, Khandwala F, Lopez R, Wachsberger DM, Richter JE, Falk GW. Barrett's esophagus at a tertiary care center: association of age on incidence and prevalence of dysplasia and adenocarcinoma. Am J Gastroenterol 2006;101:2187-93.
50. Eliakim R, Sharma VK, Yassin K, Adler SN, Jacob H, Cave DR et al. A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. J Clin Gastroenterol 2005;39:572-8.
51. Sharma P, Wani S, Rastogi A, Bansal A, Higbee A, Mathur S et al. The diagnostic accuracy of Esophageal capsule Endoscopy in patients with gastroesophageal reflux disease and Barrett's esophagus: a blinded, prospective study. Am J Gastroenterol. In press.
52. Jobe BA, Hunter JG, Chang EY, Kim CY, Eisen GM, Robinson JD et al. Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: a randomized and blinded comparison. Am J Gastroenterol 2006;101:2693-703.
53. Montgomery E, Bronner MP, Golblum JR, Greenson JK, Haber MM, Hart J et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32:368-78.
54. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006;4:566-72.
55. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-40.
56. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barren esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003;138:176-86.
57. Lightdale CJ. Esophageal cancer. American College of Gastroenterology. Am J Gastroenterol 1999;94:20-9.
58. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52.
59. Burt M. Management of malignant esophagorespiratory fistula. Chest Surg Clin N Am 1996;6:765-76.
60. Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006;131:1392-9.
61. Hanna S, Rastogi A, Weston AP, Totta F, Schmitz R, Mathur S et al. Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol 2006;101:1416-20.
62. Sharma P, Weston AP, Topalovski M, Cherian R, Bhattacharyaa A, Sampliner RE. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. Gut 2003;52:24-7.
63. Sharma P, Bansal A, Mathur S, Wani S, Cherian R, McGregor D et al. The utility of a novel narrow band imaging endoscopy system in patients with Barrett's esophagus. Gastrointest Endosc 2006;64:167-75.
64. Goda K, Tajiri H, Ikegami M, Urashima M, Nakayoshi T, Kaise M. Usefulness of magnifying endoscopy with narrow band imaging for the detection of specialized intestinal metaplasia in columnar-lined esophagus and Barrett's adenocarcinoma. Gastrointest Endosc 2007;65:36-46.
65. Kara MA, Peters FP, Rosmolen WD, Krishnadath KK, Ten Kate FJ, Fockens P et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett's esophagus: a prospective randomized crossover study. Endoscopy 2005;37:929-36.
66. Borovicka J, Fischer J, Neuweiler J, Netzer P, Gschossmann J, Ehmann T et al. Autofluorescence endoscopy in surveillance of Barrett's esophagus: a multicenter randomized trial on diagnostic efficacy. Endoscopy 2006;38:867-72.
67. Kara MA, Peters FP, Fochens P, ten Kate FJ, Bergman JJ. Endoscopic video-autofluorescence imaging followed by narrow band imaging for detecting early neoplasia in Barrett's esophagus. Gastrointest Endosc 2006;64:176-85.
68. Georgakoudi I, Jacobson BC, Van Dam J, Backman V, Wallace MB, Muller MG et al. Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus. Gastroenterology 2001;120:1620-9.
69. Kiesslich R, Gossner L, Goetz M, Dahlmann A, Veith M, Stolte M et al. In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. CHn Gastroenterol Hepatol 2006;4:979-87.
70. Rice TW, Adelstein DJ. Precise clinical staging allows treatment modification of patients with esophageal carcinoma. Oncology (Williston Park) 1997;11(9 Suppl 9):58-62.
71. Yusoff IF, Sahai AV. Staging esophageal adenocarcinoma. Semin Gastrointest Dis 2003;14:146-54.
72. Rice TW. Clinical staging of esophageal carcinoma. CT, EUS, and PET. Chest Surg Clin N Am 2000;10:471-85.
73. Scotiniotis IA, Kochman ML, Lewis JD, Furth EE, Rosato EF, Ginsberg GG. Accuracy of EUS in the evaluation of Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc 2001;54:689-96.
74. Wakelin SJ, Deans C, Crofts TJ, Allan PL, Plevris JN, Paterson-Brown S. A comparison of computerised tomography, laparoscopic ultrasound and endoscopic ultrasound in the preoperative staging of oesophagogastric carcinoma. Eur J Radiol 2002;41:161-7.
75. Kelly S, Harris KM, Berry E, Hutton J, Roderick P, Cullingworth J et al. A systematic review of the staging performance of endoscopic ultrasound in gastrooesophageal carcinoma. Gut 2001;49:534-9.
76. Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997;168:417-24.
77. Lerut T, Flamen P, Ectors N, Van Cutsem E, Peeters M, Hiele M et al. Histopathologic validation of lymph node staging with FDG-PET scans in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 2000;232:743-52.
78. Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997;64:770-6; discussion 776-7.
79. Wang KK, Wongkeesong M, Buttar NS. American Gastroenterological Association technical review on the role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 2005;128:1471-505.
80. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996;224:66-71.
81. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347;1662-9.
82. Stein HJ, Feith M, Mueller J, Werner M, Siewert JR. Limited resection for early adenocarcinoma in Barrett's esophagus. Ann Surg 2000;232:733-42.
83. Nijhawan PK, Wang KK. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointest Endosc 2000;52:328-32.
84. Ell C, May A, Pech O, Gossner L, Guenter E, Behrens A et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc 2007;65:3-10.
85. Peters FP, Kara MA, Rosmolen WD, Aalders MC, Ten Kate FJ, Bultje BC et al. Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett's esophagus. Gastrointest Endosc 2005;61:506-14.
86. Overholt BF, Lightdale CJ, Wang KK, Canto MI, Burdick S, Haggitt RC et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488-98.
87. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003;58:183-8.
88. Prasad GA, Wang KK, Buttar NS, Wongkeesong LM, Lutzke LS, Borkenhagen LS. Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc 2007;65:60-6.
89. Krishnadath KK, Wang KK, Taniguchi K, Sebo TJ, Buttar NS, Anderson MA et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 2000;119:624-30.
90. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-37.
91. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52.
92. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-84.
93. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7.
94. De Palma GD, Galloro G, Sivero L, Di Matteo E, Labianca O, Siciliano S et al. Self-expanding metal stents for palliation of inoperable carcinoma of the esophagus and gastroesophageal junction. Am J Gastroenterol 1995;90:2140-2.
95. Xinopoulos D, Dimitroulopoulos D, Moschandrea I, Skordilis P, Bazinis A, Kontis M et al. Natural course of inoperable esophageal cancer treated with metallic expandable stents: quality of life and cost-effectiveness analysis. J Gastroenterol Hepatol 2004;19:1397-402.